Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
180 Life Sciences Corp. stock logo
ATNFW
180 Life Sciences
$0.01
-4.8%
$0.01
$0.00
$0.04
N/AN/A97,681 shs9,714 shs
SXTPW
60 Degrees Pharmaceuticals
$0.06
+11.5%
$0.06
$0.01
$0.10
N/AN/A16,698 shs1,818 shs
TRSBF
3SBio
$2.90
+3.9%
$1.99
$2.22
$3.35
N/AN/A775 shs1,000 shs
Wesana Health Holdings Inc. stock logo
WSNAF
Wesana Health
$0.03
+112.6%
$0.02
$0.00
$0.15
N/AN/A27,503 shs400 shs
20 Stocks to Sell Now Cover

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
180 Life Sciences Corp. stock logo
ATNFW
180 Life Sciences
-4.76%-8.05%-1.23%+5.26%-12.09%
SXTPW
60 Degrees Pharmaceuticals
+11.46%-0.70%-8.14%+135.00%-19.43%
TRSBF
3SBio
+3.86%-1.69%+11.54%+250.28%+278.00%
Wesana Health Holdings Inc. stock logo
WSNAF
Wesana Health
+112.61%0.00%+46.24%-32.53%+88.81%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
180 Life Sciences Corp. stock logo
ATNFW
180 Life Sciences
N/AN/AN/AN/AN/AN/AN/AN/A
SXTPW
60 Degrees Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
TRSBF
3SBio
N/AN/AN/AN/AN/AN/AN/AN/A
Wesana Health Holdings Inc. stock logo
WSNAF
Wesana Health
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
180 Life Sciences Corp. stock logo
ATNFW
180 Life Sciences
0.00
N/AN/AN/A
SXTPW
60 Degrees Pharmaceuticals
0.00
N/AN/AN/A
TRSBF
3SBio
0.00
N/AN/AN/A
Wesana Health Holdings Inc. stock logo
WSNAF
Wesana Health
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
180 Life Sciences Corp. stock logo
ATNFW
180 Life Sciences
N/AN/AN/AN/AN/AN/A
SXTPW
60 Degrees Pharmaceuticals
$665.45KN/AN/AN/AN/AN/A
TRSBF
3SBio
N/AN/AN/AN/AN/AN/A
Wesana Health Holdings Inc. stock logo
WSNAF
Wesana Health
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
180 Life Sciences Corp. stock logo
ATNFW
180 Life Sciences
N/AN/A0.00N/AN/AN/AN/AN/A
SXTPW
60 Degrees Pharmaceuticals
N/AN/A0.00N/AN/AN/AN/AN/A
TRSBF
3SBio
N/AN/A0.00N/AN/AN/AN/A8/20/2025 (Estimated)
Wesana Health Holdings Inc. stock logo
WSNAF
Wesana Health
N/AN/A0.00N/AN/AN/AN/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
180 Life Sciences Corp. stock logo
ATNFW
180 Life Sciences
N/AN/AN/AN/AN/A
SXTPW
60 Degrees Pharmaceuticals
N/AN/AN/AN/AN/A
TRSBF
3SBio
N/AN/AN/AN/AN/A
Wesana Health Holdings Inc. stock logo
WSNAF
Wesana Health
N/AN/AN/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
180 Life Sciences Corp. stock logo
ATNFW
180 Life Sciences
N/A
SXTPW
60 Degrees Pharmaceuticals
N/A
TRSBF
3SBio
N/A
Wesana Health Holdings Inc. stock logo
WSNAF
Wesana Health
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
180 Life Sciences Corp. stock logo
ATNFW
180 Life Sciences
7N/AN/ANot Optionable
SXTPW
60 Degrees Pharmaceuticals
2N/AN/ANot Optionable
TRSBF
3SBio
5,411N/AN/ANot Optionable
Wesana Health Holdings Inc. stock logo
WSNAF
Wesana Health
N/AN/AN/ANot Optionable

Recent News About These Companies

Wesana Health Holdings Inc
Wesana Health Holdings Inc Sub Voting WSNAF
Wesana Health Announces Change to The Board of Directors
WSNAF Wesana Health Holdings Inc.
Wesana Health Holdings Inc. (WESA-X.CN)
Wesana Health Holdings Inc. (WSNAF)
Wesana Health Announces Voting Results of AGSM
IIROC Trade Resumption - WESA
IIROC Trading Halt - WESA
Wesana Health Announces Receipt of Short-Term Loan
Wesana Announces Second Quarter 2022 Financial Results
WESANA HEALTH HLDGS reports Q1 results
Wesana Announces First Quarter 2022 Financial Results

New MarketBeat Followers Over Time

Media Sentiment Over Time

180 Life Sciences stock logo

180 Life Sciences NASDAQ:ATNFW

$0.0080 0.00 (-4.76%)
As of 06/27/2025 03:55 PM Eastern

180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed phase 2a and phase 2b proof-of-concept clinical trials for early-stage Dupuytren's Contracture; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, that focuses on alpha 7 nicotinic acetylcholine receptor. 180 Life Sciences Corp. is headquartered in Palo Alto, California.

60 Degrees Pharmaceuticals NASDAQ:SXTPW

$0.06 +0.01 (+11.46%)
As of 06/27/2025 03:35 PM Eastern

60 Degrees Pharmaceuticals, Inc. operates as a specialty pharmaceutical company that engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19; Tafenoquine for fungal lung infections, tick-borne diseases, candidiasis, and other infectious and non-infectious diseases; and Celgosivir for respiratory viruses and dengue. The company was founded in 2010 and is based in Washington, District of Columbia.

3SBio OTCMKTS:TRSBF

$2.90 +0.11 (+3.86%)
As of 06/27/2025 03:26 PM Eastern

3SBio Inc., an investment holding company, develops, produces markets, and sells biopharmaceutical products in Mainland China and internationally. The company provides TPIAO, a recombinant human thrombopoietin to treat chemotherapy-induced thrombopenia and immune thrombocytopenia; Cipterbin, an anti-HER2 monoclonal antibody for the treatment of HER2-positive metastatic breast cancer; TNF, pre-filled aqueous injection solution. It also offers YISAIPU, the receptor fusion tumor necrosis factor inhibitor; Mandi-minoxidil tincture, an OTC external medicine for treating hair loss; EPIAO and SEPO, an erythropoietin injection; SPARIN, an injectable low-molecular-weight heparin calcium. In addition, the company provides MN709 Minoxidil Foam and Nalfuraphine hydrochloride tablets. Further, it provides trading, project management and consultation, technology, sports, financial, investment advisory, as well as manufactures medical devices; and offers agricultural services. The company has collaboration agreements with companies, such as Toray. 3SBio Inc. was founded in 1993 and is headquartered in Shenyang, the People's Republic of China.

Wesana Health stock logo

Wesana Health OTC:WSNAF

$0.03 +0.01 (+112.61%)
As of 06/27/2025 01:45 PM Eastern

Wesana Health Holdings Inc. does not have significant operations. Previously, it was developing evidence-based formulations and protocols that empower patients to overcome neurological, psychological, and mental health ailments caused by trauma. The company is headquartered in Chicago, Illinois.